Follistatin

Follistatin is a secreted glycoprotein produced in many tissues, including the gonads, pituitary, liver, kidney and skeletal muscle. It was originally characterized in ovarian follicular fluid as a factor that suppresses the secretion of follicle-stimulating hormone (FSH), which is how it got its name. Only later did researchers recognize that its central biological job is broader: follistatin acts as a high-affinity binding protein that sequesters certain members of the transforming growth factor beta (TGF-beta) superfamily and prevents them from reaching their receptors.

Two of those ligands matter most for the way follistatin is discussed in fitness and longevity circles. The first is myostatin (also called GDF-8), a muscle-derived protein that normally acts as a brake on skeletal muscle growth. The second is activin A, a related ligand with wide-ranging effects on reproduction, inflammation, fibrosis and tissue growth. By binding both, follistatin removes two negative regulators of muscle mass at the same time, which is why it attracted so much attention from muscle biologists.

It is important to be precise about terminology here, because marketing copy rarely is. Follistatin is not a short synthetic peptide like BPC-157 or TB-500. It is a folded, disulfide-rich, variably glycosylated protein. Depending on the isoform and the degree of glycosylation, reported molecular weights span roughly 31 to 49 kDa. That structural complexity has practical consequences: it affects how the molecule can be manufactured, how stable it is, whether it retains activity, and how difficult it is to verify what is actually inside a vial.

The protein is encoded by the FST gene in humans, located on chromosome 5. Alternative splicing and post-translational processing of that single gene give rise to the isoforms discussed later in this guide. Understanding that one gene generates several functionally different proteins is the key to making sense of names such as FS-288, FS-315 and FS-344, which are frequently used interchangeably online even though they do not mean the same thing.

This article is for educational purposes only and does not describe any protocol, dose or method of use. Follistatin is not approved for human use.

Follistatin works by physical obstruction rather than by signaling through a receptor of its own. Myostatin and activin normally bind activin type II receptors (ActRIIA and ActRIIB) on the cell surface, which then recruit a type I receptor and trigger intracellular Smad2 and Smad3 signaling. That signaling cascade restrains protein synthesis and muscle fiber growth. Follistatin intercepts the ligand before any of that can happen.

Structural work has clarified exactly how complete that blockade is. A crystal structure of the follistatin and activin complex published in Developmental Cell in 2005 showed that two follistatin molecules wrap around a single activin dimer, and that this arrangement antagonizes binding at both the type I and type II receptor interfaces (Thompson et al., 2005). In other words, follistatin does not merely compete for one contact point. It encircles the ligand and buries the surfaces the receptors need, which explains the very high potency observed in cell-based assays.

The pathway logic was mapped out in parallel in mouse genetics. In a 2001 study in the Proceedings of the National Academy of Sciences, Lee and McPherron showed that purified myostatin binds ActRIIB and, to a lesser degree, ActRIIA, and that this binding could be inhibited by follistatin as well as by the myostatin propeptide. They then generated transgenic mice expressing follistatin, the propeptide, or a dominant-negative form of ActRIIB under a skeletal muscle-specific promoter, and each construct produced marked increases in muscle mass comparable to myostatin knockout mice.

One nuance is frequently lost in summaries: follistatin is not a myostatin-selective agent. It also neutralizes activin A and certain bone morphogenetic proteins. Work published in Molecular Endocrinology in 2010 made the physiological consequence clear. Mice with only one functional copy of the follistatin gene showed significant reductions in muscle mass, reduced muscle function and impaired regeneration, and the authors presented genetic evidence that activin A is one of the ligands cooperating with myostatin to limit muscle growth (Lee et al., 2010). Follistatin's potency in muscle therefore reflects multi-ligand blockade, not a clean single-target effect.

That lack of selectivity cuts both ways. It is the most plausible explanation for why follistatin outperformed more selective myostatin inhibitors in rodent experiments. It is also the main reason systemic follistatin raises safety questions that a narrowly targeted anti-myostatin antibody would not.

This is where most online descriptions of follistatin fall apart. The numbers refer to different things: some count amino acids in a mature secreted protein, and one counts amino acids in a precursor encoded by a specific transcript. They are not interchangeable product grades.

The FST gene produces two principal transcripts. One encodes a 317-amino-acid precursor that, after removal of its signal peptide, yields the mature 288-residue protein known as FS-288. The other encodes a 344-amino-acid precursor that yields the mature 315-residue protein known as FS-315. A portion of FS-315 is further trimmed at the C-terminus to give a third form, FS-303. So FS-344 is best understood as the name of a transcript or cDNA, and when you see it in the literature it almost always refers to a gene therapy construct carrying that coding sequence, not to a protein someone injected.

The functional difference between isoforms is not trivial. A 2006 study in Endocrinology examined follistatin isoforms alongside follistatin-like-3 and found that activin-binding affinities were broadly comparable, but cell-surface binding differed markedly, ranking FS-288 above FS-303 above FS-315 (Sidis et al., 2006). Inhibition of endogenous activin activity tracked cell-surface binding rather than raw affinity. The explanation is a heparin-binding sequence in the N-terminal region that is functionally accessible in FS-288, letting that isoform anchor to proteoglycans at the cell surface and concentrate near where ligands act.

The practical reading is that FS-288 behaves like a locally retained, tissue-anchored inhibitor, while FS-315 behaves like a circulating reservoir. A vial label reading "follistatin 344" conveys none of this. At best it signals which coding sequence a manufacturer claims to have used; it says nothing about which mature protein is present, whether it is correctly folded, whether it is glycosylated, or whether it retains ligand-binding activity.

The animal literature is genuinely striking, and it is also the source of almost every claim made about follistatin online. Understanding what those experiments did, and did not, involve is the single most useful thing a reader can take from this guide.

The headline result comes from a 2007 paper in PLoS ONE. Se-Jin Lee reported that mice lacking myostatin and simultaneously carrying a follistatin transgene had roughly four times the muscle mass of wild-type mice, substantially more than myostatin deletion alone, which roughly doubles muscle mass. This is the origin of the "double muscled" and "quadruple muscled" mouse images that circulate on social media. The paper's actual conclusion was about biology rather than about any product: because follistatin added so much on top of a complete myostatin knockout, other ligands with myostatin-like activity must also be limiting muscle growth.

It is worth stating plainly what kind of experiment that is. These were genetically engineered animals expressing follistatin from a muscle-specific promoter, continuously and from development onward. No one injected a protein. The magnitude of the phenotype reflects lifelong genetic overexpression in a specific tissue, which is a fundamentally different exposure from an intermittent injection in an adult human.

The closest animal work to a practical intervention used viral gene delivery. A 2008 study in the Proceedings of the National Academy of Sciences compared myostatin inhibitors delivered by a single adeno-associated virus serotype 1 injection and found that the FS-344 construct produced the largest effects on muscle size and function, with gains that persisted over a two-year follow-up in mice (Haidet et al., 2008). The authors also extended the work to nonhuman primates, where increases in quadriceps size were sustained for more than a year, and reported that treated animals showed no untoward effects on cardiac pathology or reproductive capacity in that setting. That paper became the preclinical foundation for the human trials described below.

Dystrophic models have also been tested. Follistatin-derived inhibitors crossed into or delivered to mdx mice, a model of muscular dystrophy, have been reported to increase muscle mass, reduce inflammatory infiltration and improve strength. These findings are consistent and encouraging at the level of mouse pathology, but mouse dystrophy models are notoriously imperfect predictors of human outcomes, and increasing muscle bulk is not the same as correcting the underlying genetic defect.

The honest summary is that follistatin has one of the most impressive preclinical muscle-growth records of any known molecule, achieved almost entirely through genetic or viral overexpression in animals, and that this record has not translated into demonstrated human efficacy.

Human follistatin research has been conducted as gene therapy, not as protein injection. A clinical team at Nationwide Children's Hospital and Ohio State University ran small trials using an AAV1 vector carrying the FS-344 coding sequence under a CMV promoter, injected directly into muscle.

The first was a phase 1/2a trial in Becker muscular dystrophy, published in Molecular Therapy in 2015. AAV1.CMV.FS344 was delivered to six patients by direct bilateral intramuscular quadriceps injection. Three subjects received 3 × 10¹¹ vg/kg per leg and three received 6 × 10¹¹ vg/kg per leg, with distance walked on the six-minute walk test as the primary outcome. Results were mixed: in the first cohort two patients improved by 58 metres and 125 metres while the third showed no change, and in the second cohort two patients improved by 108 metres and 29 metres while the third showed no improvement. No adverse effects were encountered, and muscle biopsies showed reduced endomysial fibrosis, reduced central nucleation and a more normal fiber size distribution (Mendell et al., 2015). Note that these figures describe viral vector genomes per kilogram, a gene therapy quantity delivered by physicians under a regulatory protocol. They are not and cannot be converted into any protein dose.

The same group then reported a trial in sporadic inclusion body myositis in Molecular Therapy in 2017. Six subjects received rAAV1.CMV.huFS344 at 6 × 10¹¹ vg/kg into the quadriceps of both legs, with the six-minute walk test again as the primary outcome. The authors reported that treated subjects improved by an average of 56.0 metres per year while untreated comparison patients declined by 25.8 metres per year, alongside histological evidence of decreased fibrosis and improved regeneration (Mendell et al., 2017).

That 2017 report did not go unchallenged, and the disagreement is instructive. A letter published in the same journal later in 2017 argued that the claim of improved functional outcomes was not supported by the data presented (Greenberg, 2017), and the trial authors published a reply. Readers evaluating follistatin should know that the strongest human efficacy claim in the literature is contested in print by other specialists. The core methodological concerns are familiar ones for small open-label studies: six participants, no randomization or blinding, and comparison against a separately identified untreated group rather than a concurrent randomized control arm.

Taken together, these trials establish that intramuscular AAV1-follistatin was tolerated in a small number of carefully monitored patients and produced visible changes on biopsy. They do not establish efficacy. There is no published phase 3 trial, and no regulator has approved follistatin or an AAV-follistatin product for any indication.

This distinction is the most consequential point in this guide, because the entire online market for "follistatin 344" borrows its credibility from research that used a completely different intervention.

Every human study discussed above delivered a gene, packaged inside an engineered virus, injected into a specific muscle by a clinical team, under regulatory oversight, with biopsies and immunological monitoring. The intended outcome was for muscle cells to manufacture follistatin themselves, locally and continuously. Vials sold online claim to contain a recombinant protein, intended for injection. These are different molecules, different routes, different pharmacokinetics and different risk profiles. Evidence for one is not evidence for the other.

There is a further technical problem specific to follistatin. A correctly functioning follistatin molecule requires accurate disulfide bonding across three cysteine-rich domains and appropriate glycosylation. Products expressed in bacterial systems, improperly refolded, or degraded in transport may be immunologically active while being biologically inert, or may simply not be follistatin at all. Unlike a 15-residue synthetic peptide, a 300-residue glycoprotein cannot be meaningfully validated by the certificates of analysis typically shown by research-chemical vendors, which generally report mass and purity rather than conformational integrity or ligand-binding function.

None of this makes a conclusive negative claim about any specific vendor. The accurate statement is narrower and more useful: there is no published human pharmacokinetic, dose-finding or safety study of injected recombinant follistatin protein, so nobody, including sellers, can describe what it does in a human body with evidence. If you want a broader view of how to assess claims in this category, see our overview of peptide safety and how risk is actually assessed.

Because human exposure data are so thin, the risk discussion for follistatin is mostly mechanistic. That does not make it speculative in a loose sense. The concerns follow directly from what follistatin binds.

Reproductive and endocrine effects. Follistatin was discovered as an FSH-suppressing protein, and activin is a physiological driver of FSH secretion from the pituitary. Systemically raising follistatin activity would be expected to interfere with activin-dependent gonadotropin regulation. Animal genetics reinforce this: follistatin isoform biology is tied to fertility, and complete disruption of follistatin in mice is developmentally severe. Any intervention that broadly neutralizes activin in an adult human should be assumed to carry endocrine risk until shown otherwise.

Loss of a physiological brake. Activin and related ligands are not nuisance molecules. They participate in wound repair, immune regulation, fibrosis control and cell growth restraint. Removing that restraint over long periods has unclear consequences. Activin signaling is also a tumour-suppressive brake in several tissues, and follistatin overexpression has been studied in the context of cancer biology. This is a theoretical concern rather than a documented human harm, but it is the kind of concern that long-term controlled trials exist to resolve, and those trials have not been done.

Tendon and connective tissue mismatch. Muscle hypertrophy driven by inhibition of a growth brake does not automatically bring proportional strengthening of tendons and ligaments. This has been raised repeatedly as a concern for the whole myostatin-inhibition class. Related agents in this class, including decoy activin receptors tested as drugs, have encountered off-target problems in human trials, including nosebleeds and gum bleeding attributed to effects on other TGF-beta family ligands.

Unknown product, unknown exposure. For anyone considering an online product, the dominant risk is not follistatin pharmacology at all. It is that the contents, sterility, endotoxin load and immunogenicity of the vial are unknown. Injecting an unverified foreign glycoprotein can provoke antibody responses, including antibodies that cross-react with the body's own follistatin, with unpredictable long-term consequences.

Medical disclaimer. This section describes documented and mechanistically plausible risks for educational purposes. It is not a risk assessment for any individual. Follistatin is not approved for human use. Anyone considering any intervention affecting muscle, hormones or metabolism should consult a qualified healthcare professional, and nothing here substitutes for that consultation.

Follistatin has no marketing authorization anywhere. It is not approved by the FDA, the EMA, or any comparable regulator for any indication, in any formulation. Its only legitimate human use is as an investigational product inside an approved clinical trial, and the trials conducted so far have been AAV gene therapy studies rather than protein administration.

Products sold online are typically labeled "for research use only", a designation that means the material is not intended for human or veterinary use and has not been evaluated for safety, purity or sterility for that purpose. That label is a legal boundary, not a quality claim. Regulatory status also varies by jurisdiction: importing, possessing or supplying unapproved injectable biologics can have different legal consequences depending on where you live, and in some jurisdictions supplying them for human use is a criminal matter.

In sport, the position is unambiguous. The World Anti-Doping Agency Prohibited List places agents preventing activin receptor IIB activation under section S4 (Hormone and Metabolic Modulators), and the category explicitly names myostatin-binding proteins, giving follistatin as an example, alongside decoy activin receptors, anti-ActRIIB antibodies, agents reducing or ablating myostatin expression, and myostatin-neutralizing antibodies. Substances in this subcategory are non-specified substances, which carries the more severe default sanction framework. Separately, gene and cell doping, which is what an AAV-follistatin construct would constitute, is prohibited under the Prohibited Methods section at all times.

For any tested athlete, the practical implication is that both the protein and the gene therapy route are prohibited, in and out of competition, and that detection methods for this class continue to develop. Athletes in drug-tested federations should treat the whole myostatin inhibition category as off limits and verify current status against the list in force for the relevant year.

If your interest is in how prohibited-status compounds compare with hormonal agents in terms of legal and medical risk, our discussion of peptides versus anabolic steroids covers the regulatory contrasts in more detail.

Follistatin occupies an unusual position. Mechanistically it is among the most powerful muscle-growth interventions ever demonstrated in a mammal. Clinically it is among the least established compounds people discuss. Holding both facts at once is the correct way to think about it.

Compared with the repair-oriented peptides that dominate recovery discussions, follistatin is doing something categorically different. Those compounds are generally studied for tissue healing and inflammation in preclinical models. Follistatin targets the master regulatory brake on muscle fiber size. The potential upside is therefore much larger, and so is the systemic reach of the intervention, because the ligands it neutralizes do far more than regulate muscle. Readers comparing options across this space may find our survey of peptides studied for muscle growth and recovery useful for seeing where the evidence is thicker.

Compared with other myostatin pathway drugs, follistatin is the least selective and the least clinically advanced. Pharmaceutical companies have pursued anti-myostatin antibodies, myostatin propeptide approaches and ActRIIB-targeted agents, several of which reached mid-stage human trials. The recurring finding across that programme has been sobering: inhibiting myostatin reliably increases lean mass in humans but has repeatedly failed to deliver matching improvements in strength or function in the populations tested. That pattern is directly relevant to follistatin, and it is the main reason to be cautious about extrapolating from mouse muscle mass to human performance.

For readers encountering follistatin in bodybuilding contexts, the gap between the narrative and the evidence is the point. The quadrupled-muscle mouse is real, published and reproducible. It is also a lifelong transgenic animal, and no human has been shown to gain muscle from an injected follistatin protein in any published study. Our article on peptides in bodybuilding contexts addresses how this kind of evidence gap tends to be presented in that community.

The reasonable conclusion is that follistatin is scientifically important and practically unavailable. It remains a legitimate target for drug development, most plausibly through controlled gene delivery or engineered follistatin fusion proteins designed for selectivity, and those efforts belong in regulated trials. Educational interest in the biology is entirely appropriate. Self-administration of an unregulated version is not supported by anything in the literature.